Trial design and end points in hepatocellular carcinoma: an EASL – AASLD – ILCA consensus statement
This consensus statement recommends standardized trial designs and endpoints for hepatocellular carcinoma to improve therapeutic development and patient outcomes.
The management of hepatocellular carcinoma (HCC) has undergone radical change over the past decade. Immunotherapies now dominate the treatment of advanced‑stage disease and are increasingly being evaluated in perioperative and intermediate‑stage settings. However, in some instances, positive phase III trials have not translated into adoption by guidelines or regulatory agencies, highlighting the need to harmonize and update the current standards for trial design and end points.
Ensuring standardized trial designs enables reliable evaluation of new therapies in HCC, accelerating the development of treatments that improve patient survival and quality of life.
Bizonyítékszint: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Kapcsolódó jelek
- Quercetin suppresses the progression of HBV-associated hepatocellular carcinoma by modulating the EGFR signaling pathway
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- Surgical treatment of hepatocellular carcinoma: expert consensus statement
- Loco-regional treatment of hepatocellular carcinoma
- Real‑World Outcomes of Atezolizumab‑Bevacizumab in Hepatocellular Carcinoma: The Prospective French CHIEF Cohort